



## Chinook Therapeutics to Present at Upcoming Investor Conferences

April 11, 2023

SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the following upcoming investor conferences:

- **22<sup>nd</sup> Annual Needham Virtual Healthcare Conference** – Presentation on Monday, April 17<sup>th</sup> at 2:15 pm EDT.
- **2023 Bloom Burton & Co. Healthcare Investor Conference** – Fireside Chat on Tuesday, April 25<sup>th</sup> at 10:00 am EDT.

To access the audio webcasts and subsequent archived recording of these and other company presentations, please visit the [Investors](#) section of Chinook's website. The archived audio webcasts will remain available for replay on Chinook's website for 90 days.

### About Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook's lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody, is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 clinical trial in healthy volunteers. In addition, Chinook's research and discovery efforts are focused on building a pipeline of precision medicines for rare, severe chronic kidney diseases with defined genetic and molecular drivers. Chinook is leveraging insights from kidney single cell RNA sequencing and large CKD patient cohorts that have been comprehensively panomically phenotyped, with retained biosamples and prospective clinical follow-up, to discover and develop therapeutic candidates with mechanisms of action targeted against key kidney disease pathways. To learn more, visit [www.chinooktx.com](http://www.chinooktx.com).

### Contact:

Noopur Liffick

Senior Vice President, Investor Relations & Corporate Communications

[investors@chinooktx.com](mailto:investors@chinooktx.com)

[media@chinooktx.com](mailto:media@chinooktx.com)



Source: Chinook Therapeutics, Inc.